Literature DB >> 12117731

Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction.

Gérald Luc1, Jean-Marie Bard, Jean Ferrières, Alun Evans, Philippe Amouyel, Dominique Arveiler, Jean-Charles Fruchart, Pierre Ducimetière.   

Abstract

OBJECTIVE: We have examined the association between the incidence of coronary heart disease (CHD) and plasma high density lipoprotein (HDL) cholesterol, apolipoprotein A-I (apoA-I), and 2 HDL fractions, lipoprotein A-I and lipoprotein A-I:A-II. METHODS AND
RESULTS: These parameters were measured in subjects recruited in France and in Northern Ireland in the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study, a prospective cohort study. Among the subjects free of CHD on entry, 176 in France and 113 in Northern Ireland suffered an ischemic attack (CHD patients) during the 5-year follow-up, whereas 6612 French and 2172 Northern Irish men showed no CHD symptoms (CHD-free subjects). All 4 HDL parameter levels were lower in CHD patients than in CHD-free subjects. After the cohort was divided into quintiles based on the distribution of HDL parameter levels, a significant (P<0.0001) linear increase in relative risk was observed for each HDL parameter level. However, regression logistic analyses showed that apoA-I was the strongest predictor (more powerful than HDL cholesterol) and that lipoprotein A-I and lipoprotein A-I:A-II did not supplement apoA-I in predicting CHD.
CONCLUSIONS: Among the parameters related to HDL, apoA-I appears to be the strongest independent risk factor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12117731     DOI: 10.1161/01.atv.0000022850.59845.e0

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  33 in total

1.  Biochemical characterization of cholesteryl ester transfer protein inhibitors.

Authors:  Mollie Ranalletta; Kathleen K Bierilo; Ying Chen; Denise Milot; Qing Chen; Elaine Tung; Caroline Houde; Nadine H Elowe; Margarita Garcia-Calvo; Gene Porter; Suzanne Eveland; Betsy Frantz-Wattley; Mike Kavana; George Addona; Peter Sinclair; Carl Sparrow; Edward A O'Neill; Ken S Koblan; Ayesha Sitlani; Brian Hubbard; Timothy S Fisher
Journal:  J Lipid Res       Date:  2010-05-10       Impact factor: 5.922

2.  Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort study.

Authors:  Samia Mora; Julie E Buring; Paul M Ridker; Yadong Cui
Journal:  Ann Intern Med       Date:  2011-12-06       Impact factor: 25.391

Review 3.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study.

Authors:  Jean-Claude Ansquer; Christophe Corda; Karine Le Malicot; Valerie Jessent
Journal:  Curr Ther Res Clin Exp       Date:  2009-04

5.  Invited commentary: lipoproteins and dementia - is it the apolipoprotein A-I?

Authors:  Nikolaos Scarmeas
Journal:  Am J Epidemiol       Date:  2007-02-13       Impact factor: 4.897

Review 6.  Experimental models for the investigation of high-density lipoprotein-mediated cholesterol efflux.

Authors:  Carlos G Santos-Gallego; Chiara Giannarelli; Juan José Badimón
Journal:  Curr Atheroscler Rep       Date:  2011-06       Impact factor: 5.113

7.  Evaluation of Lipid Profile and Apolipoproteins in Essential Hypertensive Patients.

Authors:  Parsuram Nayak; Suchismita Panda; Pravat Kumar Thatoi; Roma Rattan; Srikrushna Mohapatra; Pramila Kumari Mishra
Journal:  J Clin Diagn Res       Date:  2016-10-01

Review 8.  Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk.

Authors:  Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2011-08       Impact factor: 7.616

9.  Structural Plasticity of Cholesteryl Ester Transfer Protein Assists the Lipid Transfer Activity.

Authors:  Venkat R Chirasani; Prasanna D Revanasiddappa; Sanjib Senapati
Journal:  J Biol Chem       Date:  2016-07-20       Impact factor: 5.157

Review 10.  Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.

Authors:  M John Chapman; Wilfried Le Goff; Maryse Guerin; Anatol Kontush
Journal:  Eur Heart J       Date:  2009-10-12       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.